[Federal Register: March 28, 2008 (Volume 73, Number 61)]
[Notices]               
[Page 16719-16720]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr28mr08-123]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on March 12, 2008, Sigma Aldrich 
Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 
01760-2447, made application by renewal to the Drug Enforcement 
Administration (DEA) to be registered as a bulk manufacturer of the 
basic classes of controlled substances listed in schedules I and II:

[[Page 16720]]




------------------------------------------------------------------------
                       Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235).................................  I
Methcathinone (1237).............................  I
Aminorex (1585)..................................  I
Alpha-ethyltryptamine (7249).....................  I
Lysergic acid diethylamide (7315)................  I
Tetrahydrocannabinols (7370).....................  I
4-Bromo-2,5-dimethoxy-amphetamine (7391).........  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).......  I
2,5-Dimethoxyamphetamine (7396)..................  I
3,4-Methylenedioxyamphetamine (7400).............  I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)...  I
3,4-Methylenedioxy-N-ethylamphetamine (7404).....  I
3,4-Methylenedioxymethamphetamine (MDMA) (7405)..  I
Psilocybin (7437)................................  I
5-Methoxy-N,N-diisopropyltryptamine (7439).......  I
1-[1-(2-Thienyl) cyclohexyl] piperidine (TCP)      I
 (7470).
1-Benzylpiperazine (BZP) (7493)..................  I
Heroin (9200)....................................  I
Normorphine (9313)...............................  I
Amphetamine (1100)...............................  II
Methamphetamine (1105)...........................  II
Nabilone (7379)..................................  II
1-Phenylcyclohexylamine (7460)...................  II
Phencyclidine (7471).............................  II
Cocaine (9041)...................................  II
Codeine (9050)...................................  II
Diprenorphine (9058).............................  II
Ecgonine (9180)..................................  II
Levomethorphan (9210)............................  II
Levorphanol (9220)...............................  II
Meperidine (9230)................................  II
Metazocine (9240)................................  II
Methadone (9250).................................  II
Morphine (9300)..................................  II
Thebaine (9333)..................................  II
Levo-alphacetylmethadol (9648)...................  II
Carfentanil (9743)...............................  II
Fentanyl (9801)..................................  II
------------------------------------------------------------------------

    The company plans to manufacture reference standards.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than May 27, 2008.

    Dated: March 19, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E8-6364 Filed 3-27-08; 8:45 am]

BILLING CODE 4410-09-P